joinfridays tirzepatide Eli Lilly released some preliminary results using to treat fatty liver disease (MASH) @sashahighmd #mash #nash #liverhealth #joinfridays #zepbound The JoinFridays portal has arrived!!!

Peter Balazs, a hormone and weight-loss specialist in New York and New Jersey, noted that any presentation of significant depressive symptoms, particularly those including "psychotic features and suicidal ideation," requires a full clinical evaluation

Results Study Selection and Characteristics A total of 23 phase III randomized controlled trials met the inclusion criteria, contributing 48 treatment arms conducted exclusively in individuals with T2DM (see Table 1 for a summary of trial-level and treatment-arm characteristics, and Supplementary Table S1 for detailed study characteristics)

Potential Side Effects and Considerations Common side effects of weight loss medications include gastrointestinal symptoms such as nausea, which occurs in about 44% of users, and general symptoms like headache and fatigue

We specifically chose unique prebiotics that have clinical evidence around appetite control, blood sugar control, and GLP-1. Indeed, in addition to drawing on other studies on prebiotic fibers, Supergut ran its own double-blind, placebo-controlled clinical trial, which is not yet common in this corner of the industry

Several studies are underway to determine whether this would be an effective method for patients who wish to stop using GLP-1s but still maintain their weight